

remedē[®] PATIENT AMBASSADOR PROFILE



Patient Story

Patient Name: Mike Dingledine

Spouse/Caregiver: Jane

Date of remedē implant: January 9, 2020

Patient Story: Before the remedē[®] System, it had been so long since I had a good night's sleep, I had forgotten what a restful night's sleep felt like. I was tired, worn out, and actually started feeling like giving up. I had struggled with my CPAP machine for over two years, but it just wasn't helping me. Then I learned that I had central sleep apnea (CSA), rather than the more common obstructive sleep apnea (OSA), and that a CPAP machine wasn't the answer for me.

Then I found remedē from Respicardia! It was a new technology to treat people suffering from CSA. Since my implant in January of 2020 I feel like I'm getting a new lease on life. I can sleep now and I feel rested when I wake up in the morning. My energy levels are increasing and the future looks good. I'm a happy man!

Patient Activity Level/Hobbies/Pastimes: Mike and his wife Jane are both happily retired. They have four healthy and very active grandchildren and they enjoy watching their grandchildren as they participate in a variety of youth sports and other activities. Mike also enjoys long drives in his Mini Cooper.

Pre- and Post- remedē Sleep Metrics*

Before remedē Therapy

Apnea Hypopnea Index (AHI):57.6/hr

Central Apnea Index (CAI): 34.0/hr

After remedē Therapy

Apnea Hypopnea Index (AHI): 4.3/hr

Central Apnea Index (CAI): 0.0/hr

Medical Summary

Patient Age: 69

Date of CSA Diagnosis: September 10, 2019

Other therapies tried before remedē: CPAP

Medical Team

Referring Center: The Ohio State University

Sleep Center: The Ohio State University

Implanting Center: Richard M. Ross Heart Hospital

*Sleep data obtained from patient sleep studies administered before and after remedē System treatment.

The account given is genuine and documented.

Each story represents a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to the therapy.

The table below provides median change in AHI and CAI from the **remedē** Pivotal Trial. Individual patient results may vary.

	BASELINE (N=131)	1 YEAR (N=115)	2 YEARS (N=101)	5 YEARS (N=42)
Apnea Hypopnea Index (AHI)	46 [34, 60]	18 [9, 34]	16 [7, 32]	17 [9, 34]
Central Apnea Index (CAI)	23 [13, 39]	1 [0, 4]	1 [0, 3]	1 [0, 5]

Reported as median [interquartile range].

Please speak with your doctor to determine if this therapy is right for you.
Full Important Safety Information can be found at remede.zoll.com.

Important Safety Information

The **remedē**® System is indicated for moderate to severe Central Sleep Apnea (CSA) in adult patients. Your doctor will need to evaluate your condition to determine if the **remedē** System is right for you. You will not be able to have an MRI or diathermy (special heat therapies) if you have the **remedē** System implanted. The **remedē** System may be used if you have another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting. As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection. Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The **remedē** System may not work for everyone. There are additional risks associated with removing your system. If you and your doctor decide to remove the system, another surgery will be required. Be sure to talk with your doctor so that you thoroughly understand all of the risks and benefits associated with the implantation of the **remedē** System. For further information, please visit remede.zoll.com, call 952-540-4470 or email info@remede.zoll.com. **Indication for use:** The **remedē** System is an implantable phrenic nerve stimulator indicated for the treatment of moderate to severe Central Sleep Apnea (CSA) in adult patients. **Contraindications:** The **remedē** System is contraindicated for use in patients with an active infection or patients known to require magnetic resonance imaging (MRI). See the Instructions for Use for complete information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events. **Rx Only.** The **remedē**® System, **remedē**® EL System, and **remedē**® EL-X System have received FDA approval. The **remedē**® System model 1001 has received CE Mark approval.

ZOLL MEDICAL CORPORATION

12400 Whitewater Dr., Suite 150 | Minnetonka, MN 55343 | 952-540-4470 | info@remede.zoll.com | remede.zoll.com

Copyright © 2022 ZOLL Medical Corporation. All rights reserved. Respicardia and **remedē** are registered trademarks of ZOLL Respicardia, Inc. in the United States and/or other countries. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries.

Printed in the U.S.A.
MKT 2060, Rev B

For subsidiary addresses and fax numbers, as well as other global locations, please go to www.zoll.com/contacts.

ZOLL®